dc.contributor.author |
Portmann Baracco, Arianna Sibila |
|
dc.contributor.author |
Alcorta Proaño, Rodrigo Gerónimo |
|
dc.contributor.author |
Nuñez Mochizaki, Claudia |
|
dc.contributor.author |
Webb Camminati, Camille María |
|
dc.contributor.author |
Trelles Yenque, Juan Gualberto |
|
dc.contributor.author |
Caparo Farfán, Carlos Alberto |
|
dc.contributor.author |
La Rosa de los Rios, Mauricio Francisco |
|
dc.date.accessioned |
2023-06-12T16:25:54Z |
|
dc.date.available |
2023-06-12T16:25:54Z |
|
dc.date.issued |
2023 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12866/13602 |
|
dc.description.abstract |
OBJECTIVE: Evaluate the association between SARS-CoV-2 serologic status in immunologically naïve patients and risk of preeclampsia at time of delivery. STUDY DESIGN: We conducted a retrospective cohort study of pregnant patients admitted to our institution from August 1st to September 30th, 2020. We recorded maternal medical and obstetric characteristics, and SARS-CoV-2 serologic status. Our primary outcome was the incidence of preeclampsia. Antibody testing was performed and patients were classified into seropositive groups: IgG+, IgM+, or both IgG+ and IgM+. Bivariate and multivariable analyses were performed. RESULTS: We included 275 patients that were negative for SARS-CoV-2 antibodies, and 165 that were positive. Seropositivity was not associated with higher rates of preeclampsia (p=0.183), or with preeclampsia with severe features (p=0.916) even after adjusting for maternal age> 35, BMI≥ 30, nulliparity, and previous history of preeclampsia, and type of serologic status. Previous preeclampsia had the greatest association with development of preeclampsia (OR=13.40 95% CI [4.98-36.09]; p< 0.05), and with preeclampsia with severe features (OR=5.46 95% CI [1.65-18.02]; p< 0.05). CONCLUSIONS: We found that in an obstetric population there was no association between SARS-CoV-2 antibody status and the risk of preeclampsia. |
en_US |
dc.language.iso |
eng |
|
dc.publisher |
Georg Thieme Verlag KG |
|
dc.relation.ispartofseries |
American Journal of Perinatology |
|
dc.rights |
info:eu-repo/semantics/restrictedAccess |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es |
|
dc.subject |
SARS-CoV-2 |
en_US |
dc.subject |
Antibody |
en_US |
dc.subject |
Delivery |
en_US |
dc.subject |
Risk |
en_US |
dc.subject |
Preeclampsia |
en_US |
dc.subject.mesh |
SARS-CoV-2 |
|
dc.subject.mesh |
Parto Obstétrico |
|
dc.subject.mesh |
Riesgo |
|
dc.subject.mesh |
Preeclampsia |
|
dc.title |
SARS-CoV-2 antibody status at time of delivery and the risk of preeclampsia. |
en_US |
dc.type |
info:eu-repo/semantics/article |
|
dc.identifier.doi |
https://doi.org/10.1055/a-2099-8758 |
|
dc.relation.issn |
1098-8785 |
|